mRNA / LNP CDMOs — Ranked by Signal Score · 2026
· updated as new inspection, certificate, and trial data enters the platform
35
CDMOs tracked
35
Fully scored
17
With FDA records
52
FDA inspections
183
EMA/MHRA GMP certs
2
Warning letters
On CDMO Signal's composite Signal Score, Pfizer CentreOne, BioNTech (Mfg Services), and Moderna (Contract Mfg) lead the mRNA / LNP CDMO rankings. Signal Score is a 0–100 composite of four weighted pillars — Quality Compliance (35%), Operations (25%), Financial Stability (20%), and Capacity Intelligence (20%) — built from FDA inspection history, EMA/MHRA GMP certificates, ClinicalTrials.gov sponsor footprint, and monitored capacity signals. mRNA and LNP CDMO selection turns on IVT synthesis scale, LNP formulation via microfluidics, plasmid template supply strategy, and cold-chain infrastructure. Rankings are recomputed daily. Full methodology at cdmosignal.com/methodology.
mRNA and lipid nanoparticle (LNP) manufacturing scaled rapidly after COVID-19 vaccines and now supports therapeutics across rare disease, oncology, and infectious disease. The platform pairs IVT mRNA synthesis with LNP formulation — two distinct capability sets.
Choosing an mRNA/LNP CDMO depends on IVT scale, template strategy (linearized plasmid vs PCR), LNP formulation and microfluidics, and cold-chain handling. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
FDA inspection outcomes across these CDMOs: 20 NAI (no action), 28 VAI (voluntary action), 4 OAI (official action). Leading inspection & GMP sites: United States (47), Germany (39), Italy (31), UNITED KINGDOM (21), Denmark (20).
Last updated 2026-10-06. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
PC
Pfizer CentreOne
Kalamazoo, MI · McPherson, KS
|
91.5 | 100.0 | 4 insp · 17 GMP | — | 366 programs |
| 2 |
BNT
BioNTech (Mfg Services)
Mainz, DE · Marburg, DE
|
84.9 | 100.0 | 0 insp · 8 GMP | — | 28 programs |
| 3 |
MR
Moderna (Contract Mfg)
Norwood, MA
|
81.8 | 100.0 | 2 insp · 4 GMP | — | 10 programs |
| 4 |
MK
Merck KGaA / MilliporeSigma (CDMO)
Darmstadt, DE · St. Louis, MO
|
81.8 | 98.7 | 2 insp · 2 GMP | — | 22 programs |
| 5 |
Lonza
Basel, Switzerland
|
76.0 | 95.7 | 2 insp · 8 GMP | — | 1 programs |
| 6 |
CVC
CureVac (CDMO Services)
Tubingen, DE
|
75.3 | 100.0 | 0 insp · 7 GMP | — | 4 programs |
| 7 |
NR
National Resilience
San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA
|
74.5 | 98.0 | 1 insp · 0 GMP | Available | 9 programs |
| 8 |
RP
ReciBioPharm
Keele, UK · Sodertalje, SE
|
88.0 | 100.0 | 0 insp · 3 GMP | — | 0 programs |
| 9 |
FD
FUJIFILM Diosynth Biotechnologies
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
|
84.8 | 100.0 | 0 insp · 23 GMP | 0 programs | |
| 10 |
AE
Aldevron
Fargo, ND
|
84.8 | 100.0 | 1 insp · 0 GMP | — | 0 programs |
| 11 |
WK
Wacker Biotech
Jena, DE · Amsterdam, NL · San Diego, CA
|
81.6 | 100.0 | 0 insp · 13 GMP | — | 0 programs |
| 12 |
DH
Danaher (CGT Portfolio)
Washington, DC
|
81.5 | — | — | — | 0 programs |
| 13 |
EK
Evonik Health Care
Birmingham, AL · Vancouver, BC
|
81.5 | 99.8 | 2 insp · 2 GMP | — | 0 programs |
| 14 |
CD
Corden Pharma
Plankstadt, DE · Caponago, IT · Boulder, CO
|
81.1 | 98.9 | 4 insp · 10 GMP | — | 0 programs |
| 15 |
ND
Nitto Denko Avecia
Milford, MA
|
80.3 | 100.0 | 3 insp · 0 GMP | — | 0 programs |
| 16 |
KE
Kaneka Eurogentec
Seraing, BE
|
80.3 | 100.0 | 0 insp · 4 GMP | — | 0 programs |
| 17 |
CRA
Curia (RNA/Advanced)
Albany, NY · Albuquerque, NM
|
79.4 | 99.9 | 2 insp · 18 GMP | — | 0 programs |
| 18 |
UM
MassBiologics
Boston, MA
|
79.0 | 97.2 | 1 insp · 0 GMP | — | 0 programs |
| 19 |
CC
CCRM
Toronto, ON, Canada
|
78.1 | 100.0 | 5 insp · 0 GMP | — | 0 programs |
| 20 |
PBI
ProBio
Taipei, Taiwan
|
78.1 | 100.0 | 0 insp · 9 GMP | — | 0 programs |
| 21 |
CG
Cytiva (Mfg Services)
Marlborough, MA · Uppsala, SE
|
74.0 | — | — | — | 0 programs |
| 22 |
SP
ST Pharm
Seoul, South Korea
|
73.2 | 89.4 | 2 insp · 4 GMP | — | 0 programs |
| 23 |
Catalent
Bagsværd, Denmark (operating under Novo Holdings)
|
73.1 | 74.9 | 12 insp · 37 GMP | — | 0 programs |
| 24 |
CA
Catalent (Novo Holdings)
Harmans, MD · Gosselies, BE
|
73.1 | 74.9 | 1 insp · 0 GMP | Available | 0 programs |
| 25 |
LZ
Lonza Biologics
Houston, TX · Portsmouth, NH · Geleen, NL · Basel, CH
|
73.0 | 95.7 | 1 insp · 0 GMP | Limited | 0 programs |
| 26 |
TL
TriLink BioTechnologies
San Diego, CA
|
71.0 | — | — | — | 0 programs |
| 27 |
BP
BSP Pharmaceuticals
Latina, Italy
|
70.5 | 83.6 | 7 insp · 14 GMP | — | 0 programs |
| 28 |
PN
Precision NanoSystems (Cytiva)
Vancouver, BC, Canada
|
69.0 | — | — | — | 0 programs |
| 29 |
AT
Arcturus Therapeutics (Mfg)
San Diego, CA
|
65.5 | — | — | — | 0 programs |
| 30 |
HP
HIPRA Biotech Services
Amer, Spain
|
63.0 | — | — | — | 0 programs |
| 31 |
SB
Samsung Biologics
Incheon, South Korea, Rockville, Maryland, USA
|
61.5 | — | — | Available | 0 programs |
| 32 |
RR
RiboBio
Guangzhou, China
|
59.0 | — | — | — | 0 programs |
| 33 |
AC
Acuitas Therapeutics
Vancouver, BC
|
56.5 | — | — | — | 0 programs |
| 34 |
QB
Quantoom Biosciences
Gosselies, BE
|
56.5 | — | — | — | 0 programs |
| 35 |
EH
Ethris
Planegg, DE
|
56.5 | — | — | — | 0 programs |
What to evaluate in a mRNA / LNP CDMO
IVT mRNA synthesis
Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost.
LNP formulation
LNP encapsulation via microfluidics determines potency and tolerability. Confirm lipid sourcing, formulation freedom-to-operate, and particle-size control.
Plasmid / starting material
mRNA needs a DNA template. Check whether the CDMO supplies GMP plasmid in-house or coordinates a plasmid CDMO — it affects timelines.
Cold chain & stability
mRNA-LNP products are temperature-sensitive. Evaluate frozen storage, fill-finish, and the stability program.
IVT mRNA synthesis — how do CDMOs differ on scale and capping?
IVT (in vitro transcription) is the upstream step of mRNA manufacturing, using linearized plasmid DNA or PCR products as template. CDMOs differ meaningfully on IVT batch scale (from milligrams for early clinical to multi-gram commercial), capping strategy (co-transcriptional using CleanCap or trinucleotide analogs vs enzymatic post-transcription with vaccinia D1), and template strategy (linearized plasmid is standard; PCR is faster for early work but harder to scale). Sponsors should confirm which platform the CDMO validates and how yields hold at target scale — capping efficiency directly impacts translation and immunogenicity, and cannot be corrected downstream.
LNP formulation — microfluidics, particle size, and lipid sourcing
Lipid nanoparticle (LNP) formulation is the differentiator most CDMOs are still building against. Microfluidic mixing (T-mixer or NanoAssemblr platforms) determines particle-size control, encapsulation efficiency, and reproducibility across scale-up. Ionizable-lipid supply is a real constraint — most novel LNP formulations depend on lipids from a narrow set of suppliers (Croda, Merck, Cayman) or in-house-synthesized proprietary lipids. Sponsors should ask about freedom-to-operate on the CDMO's LNP platform, GMP lipid sourcing plans, and demonstrated PDI (polydispersity index) control across process transfers.
Plasmid template supply — in-house vs sourced?
mRNA manufacturing needs GMP-grade plasmid DNA as the transcription template. CDMOs that offer both plasmid production and mRNA/LNP under one roof cut a supply seam and simplify comparability. The Plasmid DNA CDMO ranking covers the specialized plasmid manufacturers; CDMOs appearing in both mRNA and plasmid rankings offer integrated capability. For programs where plasmid is sourced externally, verify comparability data between the plasmid supplier's lots and the CDMO's validated IVT process — plasmid-to-mRNA yield is highly sensitive to plasmid quality.
How CDMO Signal computes the mRNA / LNP ranking
The mRNA / LNP Signal Score is the platform's standard four-pillar composite. Quality Compliance (35%) leans on FDA inspection classifications (NAI, VAI, OAI), Warning Letter history, and EMA/MHRA GMP certificate density. Operations (25%) reflects ClinicalTrials.gov sponsor and program footprint. Financial Stability (20%) draws on SEC filings and parent-company signals — mRNA/LNP is capital-intensive and the platform is still consolidating post-COVID, so parent-company health is a real reliability signal. Capacity Intelligence (20%) tracks monitored trade press for facility expansions and lipid-supply announcements. Full weightings at cdmosignal.com/methodology.
mRNA / LNP CDMOs — Frequently Asked Questions
Who are the top mRNA / LNP CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked mRNA / LNP CDMOs include Pfizer CentreOne, BioNTech (Mfg Services), Moderna (Contract Mfg). See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many mRNA / LNP CDMOs have FDA inspection records?
CDMO Signal tracks 17 mRNA / LNP CDMOs with FDA inspection records and 183 EMA/MHRA GMP certificates across the group.
What should I look for in an mRNA / LNP CDMO?
Look for proven IVT mRNA synthesis at your scale, LNP formulation via microfluidics, a clear template/plasmid supply strategy, cold-chain capability, and a clean FDA and EMA/MHRA record.
Do mRNA CDMOs also make the LNP and plasmid?
Capabilities vary. Some CDMOs offer end-to-end IVT mRNA, LNP formulation, and GMP plasmid; others specialize in one step and coordinate partners. Check each profile's modality coverage above.
Related modalities